ESMO: European Society for Medical Oncology

1. Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced Cervical Cancer

   Overall survival results from the second interim analysis of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

2. 10-Year Data Underscore How ICI Therapy Has Helped to Change the Long-Term Prognosis for Patients with Advanced Melanoma

   Final results from the CheckMate 067 study

3. Efficacy of Tivozanib Monotherapy in the Post-ICI Setting Among Patients with Advanced Renal Cell Cancer

   Findings from the TiNivo-2 study

4. FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Following Chemoradiation Therapy

   Evidence for efficacy is based on the results from the LAURA study

5. EMA Recommends Additional Extensions of Indications for Pembrolizumab

   New indications concern treatment of locally advanced cervical cancer in combination with chemoradiotherapy and first-line treatment of advanced or recurrent endometrial carcinoma in combination with chemotherapy